Adjuvant formulations and their mode of action.

Semin Immunol

Syntech Research, Palo Alto, CA 94304.

Published: September 1990

We have developed an adjuvant formulation (SAF) consisting of a synthetic muramyl dipeptide analogue (N-acetylmuramyl-L-threonyl-D-isoglutamine) in a squalane-Pluronic polymer emulsion. Used with a variety of antigens SAF elicits cell-mediated immunity and antibodies of protective isotypes (IgG2a in the mouse). SAF augments responses to influenza virus haemagglutinin and hepatitis B virus surface antigen. Vaccines using SAF have protected guinea pigs against genital herpes simplex virus infections and subhuman primates against Epstein-Barr virus and simian immunodeficiency virus infections. Properties of SAF are compared with those of other adjuvants, including lipopolysaccharide analogs, ISCOMs and liposomes.

Download full-text PDF

Source

Publication Analysis

Top Keywords

virus infections
8
saf
5
virus
5
adjuvant formulations
4
formulations mode
4
mode action
4
action developed
4
developed adjuvant
4
adjuvant formulation
4
formulation saf
4

Similar Publications

Reduced SARS-CoV-2 Infection Rates in Lab Workers Conducting Nucleic Acid Testing: Controlling for the Healthy Worker Effect.

J Epidemiol Glob Health

January 2025

Center of Clinical Laboratory, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, No.201-209 Hubinnan Road, Xiamen, 361004, China.

Background: During the COVID-19 outbreak in December 2022 in China, some laboratory workers in SARS-CoV-2 nucleic acid testing (NAT) laboratories remained uninfected.

Objectives: To evaluate if the incidence of SARS-CoV-2 infection was reduced in laboratory workers who performed SARS-CoV-2 NAT, and whether this reduction resulted from the healthy worker effect.

Methods: This retrospective cohort study included 423 laboratory workers from 14 SARS-CoV-2 NAT laboratories in Xiamen, China.

View Article and Find Full Text PDF

Liver Enzyme Elevation After Hepatitis C Virus Cure: Is There a Sex Effect? (ANRS CO13 HEPAVIH Cohort).

J Viral Hepat

March 2025

Aix Marseille Univ, Inserm, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM, Marseille, France.

View Article and Find Full Text PDF

Current guidelines to prevent hepatocellular carcinoma (HCC) by chronic hepatitis B virus (HBV) infection are based on risk assessments that include age, sex, and virological and biochemical parameters. The study aim was to investigate the impact of predictive markers on long-term outcomes. The clinical outcomes of 100 patients with chronic hepatitis B were investigated 30 years after a baseline assessment that included liver biopsy.

View Article and Find Full Text PDF

Alpha-fetoprotein (AFP) level and its changes in chronic hepatitis B (CHB) may influence the risk of future hepatocellular carcinoma (HCC). This study aims to evaluate the HCC risk in CHB patients with no overt HCC but with elevated AFP level and to explore the prognostic role of longitudinal changes in AFP and liver-related laboratory values. This multicentre cohort study included 10,639 CHB patients without a history of HCC from seven medical facilities in South Korea.

View Article and Find Full Text PDF

Epstein-Barr virus-associated smooth muscle tumors (EBV-SMTs) represent a rare category of soft tissue tumors that are predominantly seen in individuals with compromised immune systems. Pathologically, EBV-SMT has malignant potential because of its unpredictable nature. These tumors can manifest at various anatomical sites or even multiple lesions in different locations.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!